Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00236171
Recruitment Status : Completed
First Posted : October 12, 2005
Last Update Posted : June 8, 2010
Information provided by:
Technische Universität Dresden

Brief Summary:
The purpose of this study is to evaluate the efficacy of the topical therapies Protopic and Advantan as well as their combination against placebo in a Psoriasis Plaque Test

Condition or disease Intervention/treatment Phase
Psoriasis Vulgaris Drug: Protopic, Advantan Procedure: Blood and Urine Test Procedure: coherence tomography Not Applicable

Detailed Description:
daily psoriasis plaque tests for two weeks and optical coherence tomography (OCT) and 20-MHz-ultrasound on day 0 and day 11, 10 days post end of treatment and 20 days post end of treatment

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test
Study Start Date : September 2004
Actual Primary Completion Date : April 2006
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
U.S. FDA Resources

Primary Outcome Measures :
  1. sum score of psoriasis plaque tests on day 11

Secondary Outcome Measures :
  1. 20-MHz-ultrasound and OCT on day 11

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients older than 18 Years
  • Negative urine pregnancy test
  • Written informed consent
  • Good compliance

Exclusion Criteria:

  • Patients less than 18 years
  • Pregnant patients
  • Patients with renal insufficiency, liver diseases
  • Patients who received systemic antipsoriatic treatment or UV treatment less than 4 weeks prior to study
  • Patients who used topical antipsoriatics within two weeks prior to study
  • Immunosuppressed Patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00236171

Technische Universität Dresden
Dresden, Sachsen, Germany, 0351
Sponsors and Collaborators
Technische Universität Dresden
Principal Investigator: Gottfried Wozel, Professor Technische Universität Dresden

Responsible Party: Gottfried Wozel, MD, Technical University Dresden Identifier: NCT00236171     History of Changes
Other Study ID Numbers: ETAPSO
First Posted: October 12, 2005    Key Record Dates
Last Update Posted: June 8, 2010
Last Verified: June 2010

Keywords provided by Technische Universität Dresden:
topical therapy
Psoriasis Plaque Test

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases